Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study

Sirio Fiorino, Michela Visani, Michele Masetti, Giorgia Acquaviva, Giovanni Tallini, Antonio De Leo, Adele Fornelli, Moira Ragazzi, Francesco Vasuri, Daniela Grifoni, Chiara Maria Argento, Thais Maloberti, Matteo Ravaioli, Carlo Fabbri, Elio Jovine, Annalisa Pession, Dario de Biase

Research output: Contribution to journalArticlepeer-review

Abstract

Pancreatic adenocarcinoma (PDAC) is the most frequent histological type of malignancy in the pancreas. Extracellular matrix (ECM), plays a critical role during the process of human carcinogenesis and the possible diversity in matricellular proteins composition of ECM may have a significant impact on the clinical course of PDAC. Aim of this paper was to evaluate the expression of three matricellular proteins, including Periostin (POSTN), Tenascin (TNS) and Osteopontin (OPN), in PDAC from long-survival (LS) and non-long survival (NLS) patients. A total of 30 PDAC were analyzed, 15 from patients that survived more than 60 months after surgery (LS) and 15 that died from the disease within 24 (NLS). RNA was extracted and OPN, TNS and POSTN mRNA levels were evaluated by qRT-PCR. LS and NLS samples showed the same type of POSTN and TN isoforms. On the contrary, OPN seems to be preferentially expressed in NLS PDAC. Moreover, OPNb and OPNc isoforms were expressed exclusively in NLS samples. In conclusion, Our data led to hypothesize a possible relationship between the expression of different isoforms of each of these proteins and the clinical outcome of patients with PDAC.

Original languageEnglish
Pages (from-to)8235-8241
Number of pages7
JournalMolecular Biology Reports
Volume47
Issue number10
DOIs
Publication statusPublished - Oct 2020

Fingerprint Dive into the research topics of 'Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study'. Together they form a unique fingerprint.

Cite this